Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15496456 | 0.79 | — | — | |
| SCHEMBL26625683 | 0.75 | — | — | |
| SCHEMBL23270091 | 0.75 | — | — | |
| SCHEMBL6417096 | 0.75 | — | — | |
| SCHEMBL26625690 | 0.75 | — | — | |
| SCHEMBL4600025 | 0.75 | TDP1 (0.33) | — | |
| SCHEMBL31751606 | 0.75 | TDP1 (0.33) | — | |
| SCHEMBL2636857 | 0.74 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL4180706 | 0.73 | PGD (0.33) | — | |
| SCHEMBL4180699 | 0.73 | PGD (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2025667-B1 | 9,10-SECOPREGNANE DERIVATIVE AND PHARMACEUTICAL | NIPPON SHINYAKU CO LTD (JP) | 2016-08-10 | — | — | EP | disclosed |
| US-8796246-B2 | 9, 10-secopregnane derivative and pharmaceutical | NIPPON SHINYAKU CO., LTD. (JP) | 2014-08-05 | — | — | US | disclosed |
| US-20100130454-A1 | 9,10-SECOPREGNANE DERIVATIVES AND MEDICINE | NIPPON SHINYAKU CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100016263-A1 | 9, 10-SECOPREGNANE DERIVATIVE AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2025667-A1 | 9,10-SECOPREGNANE DERIVATIVE AND PHARMACEUTICAL | Nippon Shinyaku Co., Ltd. (JP) | 2009-02-18 | — | — | EP | disclosed |
| EP-1829860-A1 | 9,10-SECOPREGNANE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130454-A1 | 9,10-SECOPREGNANE DERIVATIVES AND MEDICINE | VDR, CYP2R1, CYP24A1 | ALDH1A1 3069/4885FFAR1 79/4885 |
| US-20100016263-A1 | 9, 10-SECOPREGNANE DERIVATIVE AND PHARMACEUTICAL | CYP2R1, VDR, CYP24A1 | ALDH1A1 3019/4885FFAR1 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.